Topic:
Drug Safety
Latest Headlines
Latest Headlines
FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
FDA staffers found clear evidence to prove that Merck's blockbuster drug candidate suvorexant is quite effective in promoting sleep, but the internal review cites multiple safety issues for the high doses studied in clinical trials.
Australian judge kills Merck Vioxx class action settlement
A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Novartis properly warned of Zometa's risks, jury decides
Novartis prevailed in the latest court battle over jawbone injuries in Zometa patients. The company did properly warn patients about the drug's risks, a New Jersey jury determined after a 13-day trial.
Jury is out in another case linking Novartis' Zometa to jawbone death
Novartis is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng's claims that the Swiss drugmaker downplayed the bone drug's risks.
Ranbaxy inks record-setting $500M manufacturing settlement with the feds
The India-based generics maker pleaded guilty to U.S. drug safety violations and agreed to pay $500 million in penalties, in the largest-ever federal settlement with a maker of copycat drugs.
Mobile service PharmaSecure finds demand in losing fight against fake drugs
PharmaSecure has expanded rapidly as the pharma industry seeks to authenticate its goods amid out-of-control counterfeiting. Patients might have the most at stake in verification of medicines, with fake drugs blamed for killing thousands of people annually.
WSJ: J&J federal Risperdal deal hung up on language over breasts
Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.
J&J issue in South Korea reminiscent of OTC problems here
Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
Z-Pak's fatal risks don't apply to the average patient, new study finds
The popular Z-Pak antibiotic, linked to heart-rhythm problems in March, may not be risky for the average patient, a new study suggests.
Takeda persuades Actos judge to toss $6.5M jury verdict
The $6.5 million jury verdict in Takeda Pharmaceuticals' first Actos trial didn't last long. Judge Kenneth Freeman tossed out the jury's judgment, saying that plaintiffs' lawyers didn't prove that Jack Cooper's bladder cancer was linked to his use of Actos.
